Strategic partnership Leinco has formal collaboration activity with CellCarta and is actively expanding proteomics capabilities, presenting a joint-solution selling angle to customers seeking integrated antibody/protein development with advanced proteomics.

AI driven tools The launch of the Leinco Antibody Advisor signals a tech-forward approach that can be positioned as a differentiator to clients needing faster antibody selection and design, enabling upsell opportunities to enhanced service packages.

Clinical and therapeutic focus With capabilities in antibodies and proteins for immuno-oncology and in vivo/in vitro assays, target potential buyers in biotech and pharma seeking high-purity reagents and custom development for translational research and early clinical programs.

Quality and compliance ISO 9001 and ISO 13485 certification underscores reliability and quality risk reduction, making Leinco an attractive partner for regulated projects, quality-focused labs, and contract manufacturing opportunities.

Funding and validation Significant external momentum including a Gates Foundation grant and ongoing expansions suggest credibility and financial backing, which can be leveraged when engaging institutions and grant-funded research teams seeking collaborators with proven support.